For the year ending 2026-01-31, TGT had $726M increase in cash & cash equivalents over the period. $2,835M in free cash flow.
| Cash Flow | 2026-01-31 | 2025-02-01 | 2024-02-03 | 2023-01-28 |
|---|---|---|---|---|
| Net earnings | 3,705 | 4,091 | 4,138 | 2,780 |
| Depreciation and amortization | 3,134 | 2,981 | 2,801 | 2,700 |
| Share-based compensation expense | 281 | 304 | 251 | 220 |
| Deferred income taxes | -55 | -180 | 298 | 582 |
| Gain on dermstore sale | - | - | 0 | 0 |
| Loss on debt extinguishment | - | - | - | 0 |
| Noncash (gains) / losses and other, net | 100 | -26 | -94 | -172 |
| Inventory | -436 | 854 | -1,613 | -403 |
| Other assets | 494 | 308 | 85 | -22 |
| Accounts payable | -501 | 1,008 | -1,216 | -2,237 |
| Accrued and other liabilities | 156 | 299 | 727 | -624 |
| Cash provided by operating activities | 6,562 | 7,367 | 8,621 | 4,018 |
| Expenditures for property and equipment | 3,727 | 2,891 | 4,806 | 5,528 |
| Proceeds from disposal of property and equipment | - | 3 | 24 | 8 |
| Proceeds from dermstore sale | - | - | 0 | 0 |
| Other | -78 | -28 | -22 | -16 |
| Cash used in investing activities | -3,649 | -2,860 | -4,760 | -5,504 |
| Additions to long-term debt | 1,984 | 741 | 0 | 2,625 |
| Reductions of long-term debt | 1,643 | 1,139 | 147 | 163 |
| Dividends paid | 2,053 | 2,046 | 2,011 | 1,836 |
| Repurchase of stock | 408 | 1,007 | 0 | 2,826 |
| Shares withheld for taxes on share-based compensation | 67 | 99 | 127 | - |
| Stock option exercises | - | 0 | 0 | 4 |
| Cash used in financing activities | -2,187 | -3,550 | -2,285 | -2,196 |
| Net increase in cash and cash equivalents | 726 | 957 | 1,576 | -3,682 |
| Cash and cash equivalents at beginning of period | 4,762 | 3,805 | 2,229 | 5,911 |
| Cash and cash equivalents at end of period | 5,488 | 4,762 | 3,805 | 2,229 |
TARGET CORP (TGT)
TARGET CORP (TGT)